Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline
🤖 D.R.A.F.T. Summary
PARIS, FRANCE, 22 JULY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody. About potravitugPotravitug is a first-in-class monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.
Outlets covering this story
Financial Post
CENTER
Only one perspective covered this story — no diversity detected
Side-by-Side Outlet Comparison — Starter+
See how 1 outlets framed this story — bias by source, F.A.C.T. framing analysis, and verdict side by side.
Unlock with Starter →